Amedisys Inc (NASDAQ:AMED) – Equities researchers at Oppenheimer issued their Q1 2019 earnings per share (EPS) estimates for shares of Amedisys in a note issued to investors on Tuesday. Oppenheimer analyst M. Wiederhorn forecasts that the health services provider will post earnings of $0.63 per share for the quarter. Oppenheimer also issued estimates for Amedisys’ Q2 2019 earnings at $0.71 EPS, Q3 2019 earnings at $0.71 EPS, Q4 2019 earnings at $0.74 EPS and FY2019 earnings at $2.79 EPS.
AMED has been the topic of several other research reports. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $55.00 to $65.00 in a report on Thursday, November 2nd. Benchmark upgraded Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a report on Thursday, November 2nd. Craig Hallum reiterated a “buy” rating and issued a $68.00 price objective (up previously from $55.00) on shares of Amedisys in a report on Thursday, November 9th. Jefferies Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Thursday, October 12th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $61.00.
Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The company had revenue of $380.20 million for the quarter, compared to the consensus estimate of $384.59 million. During the same quarter in the previous year, the business earned $0.36 earnings per share. The company’s revenue for the quarter was up 5.1% on a year-over-year basis.
Hedge funds and other institutional investors have recently modified their holdings of the business. UBS Asset Management Americas Inc. increased its holdings in Amedisys by 23.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock worth $915,000 after purchasing an additional 2,812 shares during the period. Wells Fargo & Company MN increased its holdings in Amedisys by 29.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after purchasing an additional 339,825 shares during the period. Castleark Management LLC purchased a new stake in Amedisys during the 2nd quarter worth about $3,674,000. Assenagon Asset Management S.A. purchased a new stake in Amedisys during the 3rd quarter worth about $1,212,000. Finally, Bank of New York Mellon Corp increased its holdings in Amedisys by 10.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock worth $47,375,000 after purchasing an additional 82,247 shares during the period. Institutional investors own 94.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Amedisys Inc (AMED) Forecasted to Earn Q1 2019 Earnings of $0.63 Per Share” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://stocknewstimes.com/2018/01/19/amedisys-inc-amed-forecasted-to-earn-q1-2019-earnings-of-0-63-per-share.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.